Journal
CELLULAR IMMUNOLOGY
Volume 297, Issue 1, Pages 46-52Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2015.06.003
Keywords
Livin alpha; Recombinant adenoviral vector; Gene therapy; Dendritic cell; Tumor cell
Categories
Funding
- Project of Natural Science Foundation of China [81160294]
- Science and Technology Research Program of Jiangxi Provincial Education Department [GJJ13161]
- Key Project of Science and Technology Research Foundation of Hubei Province [2007JX3A05]
Ask authors/readers for more resources
Transduction with recombinant, replication-defective adenoviral (rAd) vectors encoding a transgene is an efficient method for gene transfer into human dendritic cells (DCs). Livin is a good candidate for cancer immunotherapy since it is overexpressed in most common human cancers, poorly expressed in most normal adult tissues. Two splicing variants of livin, designated livin alpha and livin beta, have been identified. In this study, we used human livin a recombinant adenovirus (rAd-hlivin alpha) to transduced DCs. We found that DCs transduced with rAd-hlivin alpha (rAd-hlivin alpha DCs) could effectively induce human livin alpha specific cytotoxic T lymphocytes (CTL) in vitro against various tumor cell lines. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available